Skip Navigation
Explore our COVID-19 Resources and Updates
We've been notified of a phishing attack that impersonates our daily email. We don't send attachments in our daily update. Please double check the email address of sender and don't download files or click on links from unknown sources.
CHS blue logo square
 
 
Home > Our Work > All Publications > 2020

Publications

Our publications keep professionals working across the public, private, and academic sectors informed on the most important developments and issues in health security and biosecurity.

Find an article or report by keywords:

 
 
Find an article or report or see all by area, author, or year:

Title:

Enabling Emergency Mass Vaccination: Innovations in Manufacturing and Administration During a Pandemic

Authors:
Divya Hosangadi; Kelsey Lane Warmbrod; Elena K Martin; Amesh Adalja; Anita Cicero; Thomas Inglesby; Crystal Watson; Matthew Watson; Nancy Connell
Date posted:
April 21, 2020
Publication type:
Article
Publication:
Vaccine
Publisher:
Elsevier Science
DOI:
10.1016/j.vaccine.2020.04.037
Availability:
Available on publisher's website
See also:
Introduction:

The global reach of infectious disease pandemics typically necessitates a similarly ubiquitous public health intervention: mass vaccination. The development and large-scale deployment of a vaccine requires substantial investment and a coalition of stakeholders to undertake research and development (including phase I to III clinical trials), manufacturing, and widespread administration. Recent efforts by national and international funders and researchers to advance the state of vaccinology for pandemics and other infectious disease emergencies have focused largely on expediting the R&D phase1. There has been comparatively less attention paid to modernizing, optimizing, and therefore accelerating other aspects of the vaccine enterprise—namely, manufacturing, distribution, and administration. The current COVID-19 pandemic plainly underscores the need to vastly accelerate mass vaccination in every phase.

We have conducted two qualitative research studies on vaccine manufacturing and administration capabilities in the context of infectious disease emergencies and have authored two forthcoming reports (Mass Vaccination 2.0: A Survey of New Technologies and Strategies and Vaccine Capacity for Global Pandemics: Manufacturing and Distribution). Here, we seek to apply findings and lessons from that work to inform the vaccine response to COVID-19.

 

 

Our Mission

To protect people’s health from epidemics and disasters and ensure that communities are resilient to major challenges.